The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society

Abrams, Paul; Cardozo, Linda; Fall, Magnus; Griffiths, Derek; Rosier, Peter; Ulmsten, Ulf; Kerrebroeck, Philip Van; Victor, Arne; Wein, Alan J.

doi:10.1002/nau.10052

Cited by 6,559 publications

(3,528 citation statements)

References 15 publications

Supporting

Mentioning

3,270

Contrasting

Unclassified

234

Order By: Relevance

“…1,2 The symptoms of urinary urgency, with or without urinary incontinence, increased daytime frequency and nocturia, 3 together with various comorbidities, 4,5 can have a devastating effect on quality of life. 6 The principal drugs used for OAB are antimuscarinic agents.…”

Section: Introductionmentioning

confidence: 99%

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

Wagg¹,

Franks²,

Ramos³

et al. 2015

CUAJ

104

132

View full text Add to dashboard Cite

Introduction: Antimuscarinics are the principal pharmacological treatment for overactive bladder (OAB), but frequently give rise to anticholinergic side effects, such as dry mouth, a factor leading to poor persistence. The ß 3 -adrenoceptor agonist mirabegron is devoid of significant anticholinergic activity, while being effective in OAB. We evaluated persistence and adherence with mirabegron versus antimuscarinics over 12 months. Methods: We obtained retrospective claims from a Canadian Private Drug Plan database for patients 18 years old and over, with a first claim for mirabegron or antimuscarinics during a 6-month index period (April-September 2013). A 6-month look-back identified those with no prior claims for OAB medication (treatmentnaïve) or ≥1 prior OAB drug (treatment-experienced). Time to end of persistence (≥30 day therapy gap or switch of therapy) was evaluated over 12 months; adherence with medication (medication possession ratio) was also measured. Results: Persistence data from 19 485 patients (74% female, 92% naïve, 19.9% aged ≥65 years) showed that for experienced patients the median number of days on mirabegron was 299 days, compared with a range of 96 to 242 days for the different antimuscarinics; for naïve patients, it was 196 versus 70 to 100 days, respectively. Persistence at 12 months was for mirabegron 39% versus 14% to 35% for antimuscarinics, (experienced) and 30% mirabegron versus 14% to 21% antimuscarinics, (naïve). Patients taking mirabegron demonstrated statistically significantly greater adherence than those taking antimuscarinics. Conclusion: Patients who received mirabegron remained longer on treatment than those treated with antimuscarinics, and had higher 12-month persistence and adherence rates.

show abstract

Section: Introductionmentioning

confidence: 99%

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

Wagg¹,

Franks²,

Ramos³

et al. 2015

CUAJ

104

132

View full text Add to dashboard Cite

show abstract

“…Data were interpreted in accordance with the International Urogynecological Association (IUGA) and International Continence Society (ICS) guidelines. 4,5 The quality of life was measured by the urinary incontinence-specific quality of life (I-QoL) questionnaire, with 22 items in I-QoL summed and then transformed to a 0-100 scale for greater interpretability, with higher scores representing greater QoL. 6,7 …”

Section: Subjectsmentioning

confidence: 99%

A sequential comparison of postoperative voiding function between two different transobturator sling procedures

Choi

Jung

Lee

et al. 2016

CUAJ

View full text Add to dashboard Cite

Introduction: We evaluated sequential postoperative voiding function of two types of sling procedures (Monarc ® and ALIGN ® ) in patients with stress urinary incontinence. Methods: Ninety-one women diagnosed with urodynamic stress incontinence were randomly assigned to the study. All enrolled patients underwent Monarc or ALIGN procedure. They were postoperatively evaluated at one day, one week, one month, three months, 12 months, and 24 months. The voiding function was evaluated with uroflowmetry and post-void residual urine. Patients were asked if voiding had changed after surgery and had to complete the incontinence quality of life scale (I-QoL) questionnaire at 12 months. Results: The Monarc (n=47) and ALIGN (n=44) groups had similar demographic characteristics. The maximal flow rate (Qmax) was significantly decreased on the first day after surgery and gradually increased during the following weeks. Comparing the two groups at one week, the ALIGN group had a significantly decreased Qmax than the Monarc group (17.6 ± 5.2 vs. 20.7 ± 5.0; p=0.004). However, at one, three, 12, and 24 months, there were no significant differences between the two groups. Conclusions: This study demonstrated that an absorbable tensioning suture in the Monarc mesh could increase Qmax compared to ALIGN at one week after surgery. An absorbable tensioning suture may reduce the risk of an early postoperative voiding dysfunction compared to other meshes that do not have this.

show abstract

“…Bladder compliance (BC) describes the relationship between the change in bladder volume and change in detrusor pressure [1]. Low BC manifests as a steep rise in detrusor pressure during bladder filling [2].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Outcome of Botulinum Toxin Type A for Patients with Low Bladder Compliance Secondary to Spinal Cord Injury

Chen¹,

Huang²,

Huang³

et al. 2017

OJU

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of botulinum toxin type A (BTX-A) in treating patients with low bladder compliance (BC) secondary to spinal cord injury (SCI). Methods: From 2011 to 2016, we retrospected patients who received BTX-A injections for LBC secondary to SCI. The primary outcomes were urodynamic parameters including maximum detrusor pressure (Pdetmax), bladder compliance (BC). Related adverse events were recorded. Results: 72 SCI patients were selected (62 males, 10 females, age range 18 -52 years; mean age 28.5 years). 12 weeks after BTX-A injection, Pdetmax decreased from 51.02 cmH 2 O to 28.31 cmH 2 O. BC increased from 3.64 ml/cmH 2 O to 10.08 ml/cmH 2 O. 12 patients had mild transient haematuria for 1 -2 days. Conclusion: Intradetrusor BTX-A injection was effective and safe for patients with low BC secondary to SCI.

show abstract

The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society

Cited by 6,559 publications

References 15 publications

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in Canada

A sequential comparison of postoperative voiding function between two different transobturator sling procedures

Therapeutic Outcome of Botulinum Toxin Type A for Patients with Low Bladder Compliance Secondary to Spinal Cord Injury

Contact Info

Product

Resources

About